[Immunohistochemical study of dihydropyrimidine dehydrogenase (DPD) and p53 in biopsied specimens of esophageal cancer before chemoradiotherapy].
We studied whether the immunohistochemical status of dihydropyrimidine dehydrogenase (DPD) and p53 can be used to predict the sensitivity to chemoradiotherapy (CRT) in patients with esophageal cancer. In 19 patients who did not undergo preoperative CRT, the immunoreactivity of DPD and p53 in biopsied specimens correlated well with those in surgically resected specimens (DPD: 100%, p53: 73%). Fifteen patients were treated with 5-FU (250-300 mg/body/day: day 1-5, 8-12), low-dose cisplatin (10 mg/body/day: day 1, 8) and radiotherapy (30-40 Gy). The response rate (CR + PR) for CRT in these patients was 40%. All tumors that showed CR or PR demonstrated low expression of DPD. However, all tumors with high DPD expression showed MR or NC. However, the expression of p53 did not correlate with the response rate for CRT. Therefore, the effect of CRT for esophageal cancer may be predicted by immunohistochemical examination of DPD in biopsied tumor specimens.
Hisamitsu
K
K
Dept. of Surgery I, Faculty of Medicine, Tottori University.
Fukuda
K
K
Oka
S
S
Yamaguchi
K
K
Katano
K
K
Ikeguchi
M
M
Tsujitani
S
S
Kaibara
N
N
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001706:Biopsy; D002945:Cisplatin / Q000008:administration & dosage; D042943:Dihydrouracil Dehydrogenase (NADP); D004938:Esophageal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy; D004947:Esophagus / Q000473:pathology; D005472:Fluorouracil / Q000008:administration & dosage; D005544:Forecasting; D006801:Humans; D007150:Immunohistochemistry; D010088:Oxidoreductases / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
D016159:Tumor Suppressor Protein p53; D010088:Oxidoreductases; D042943:Dihydrouracil Dehydrogenase (NADP); D002945:Cisplatin; D005472:Fluorouracil